car-t cell therapy eligibility

car-t cell therapy eligibility

Why 3 Chronic Disease Management Myths Block CAR‑T Access

Myths that chronic disease patients are "too fragile" for CAR-T, that B-cell depletion is unsafe, and that autoimmune trials only accept the young create invisible barriers to CD19 CAR-T therapy. In reality, the CASTLE basket trial defined clear, data-driven criteria that can guide clinicians today. Globally, more than